Lepu Biopharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	853.03	401.29	426.02	669.4	155.17
Short-Term Investments	-	11.08	8.78	8.81	59.07
Trading Asset Securities	105.73	63.63	63.63	-	-
Cash & Short-Term Investments	958.76	475.99	498.43	678.2	214.24
Cash Growth	101.42%	-4.50%	-26.51%	216.57%	-71.86%
Accounts Receivable	66.88	45.82	37.8	3.04	-
Other Receivables	64.83	35.97	17.37	22.3	0.07
Receivables	131.71	81.79	55.17	25.34	0.07
Inventory	51.83	22.79	29.41	24.06	24.18
Prepaid Expenses	-	63.89	89.36	81.62	73.34
Other Current Assets	-	1.05	4.78	3.58	2.3
Total Current Assets	1,142	645.51	677.15	812.8	314.13
Property, Plant & Equipment	1,027	1,051	1,087	1,039	978.44
Long-Term Investments	397.35	114.07	126.69	122.39	137.97
Goodwill	-	52.64	52.64	52.64	52.64
Other Intangible Assets	501.07	382.61	381.59	398.18	422.45
Other Long-Term Assets	31.56	34.82	59.01	104.1	176.43
Total Assets	3,100	2,281	2,384	2,529	2,082
Accounts Payable	183.83	236.14	207.61	166.13	158.82
Accrued Expenses	-	34.48	32.88	32.51	23.96
Short-Term Debt	-	-	-	329.63	40.41
Current Portion of Long-Term Debt	756.32	538.41	434.3	30.36	20
Current Portion of Leases	26.21	44.36	28.34	37.17	22.91
Current Income Taxes Payable	-	16.91	1	1.51	1.94
Current Unearned Revenue	0.41	0.91	-	-	4
Other Current Liabilities	195.29	172.31	195.43	246.49	277.02
Total Current Liabilities	1,162	1,044	899.56	843.79	549.06
Long-Term Debt	275.55	255.94	260	290.06	232.47
Long-Term Leases	-	11.46	24.18	3.09	19.48
Long-Term Unearned Revenue	17.66	18.02	12	12	12
Long-Term Deferred Tax Liabilities	37.69	37.69	37.69	37.69	37.69
Other Long-Term Liabilities	243.92	232.27	262.17	441.79	384.29
Total Liabilities	1,737	1,599	1,496	1,628	1,235
Common Stock	1,804	1,711	1,659	1,659	1,532
Additional Paid-In Capital	-	2,578	2,420	2,420	1,842
Retained Earnings	-2,504	-2,765	-2,354	-2,331	-1,642
Comprehensive Income & Other	2,086	-820.49	-828.8	-847.04	-894.2
Total Common Equity	1,386	702.83	896.91	900.76	836.71
Minority Interest	-23.5	-21.02	-8.21	-	10.37
Shareholders' Equity	1,363	681.8	888.7	900.76	847.08
Total Liabilities & Equity	3,100	2,281	2,384	2,529	2,082
Total Debt	1,058	850.16	746.82	690.3	335.26
Net Cash (Debt)	-99.32	-374.17	-248.4	-12.1	-121.03
Net Cash Per Share	-0.06	-0.22	-0.15	-0.01	-0.08
Filing Date Shares Outstanding	1,774	1,711	1,659	1,659	1,659
Total Common Shares Outstanding	1,774	1,711	1,659	1,659	1,532
Working Capital	-19.77	-398.01	-222.42	-30.99	-234.93
Book Value Per Share	0.78	0.41	0.54	0.54	0.55
Tangible Book Value	885.23	267.58	462.68	449.95	361.62
Tangible Book Value Per Share	0.50	0.16	0.28	0.27	0.24
Buildings	-	660.23	45.55	45.55	-
Machinery	-	378.64	365.38	246.16	195.06
Construction In Progress	-	22.38	628.15	661.64	633.35
Leasehold Improvements	-	118.91	106.03	105.71	102.42

Source: S&P Global Market Intelligence. Standard template. Financial Sources.